Evidence map›Paper›PMID 40510236›Full record

ReviewOncology letters2025

Development and challenges in the treatment of advanced gallbladder cancer (Review).

Bo Zhou, Shi-Ran Zhang, Geng Chen

Abstract readReview
In one paragraph

Review in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Bo ZhouDepartment of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China.
Shi-Ran ZhangDepartment of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China.
Geng ChenDepartment of Hepatobiliary Surgery, Daping Hospital, Army Medical University, Chongqing 400042, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gallbladder cancer (GBC) is a highly lethal disease and the most common cancer of the biliary tract. Numerous patients are diagnosed at an advanced stage, limiting surgical options and necessitating local or systemic treatment. Despite advancements in cancer treatment, 5-year survival rates remain low. Various therapeutic methods are available for the treatment of advanced GBC, including local therapy, chemoradiotherapy, immunotherapy and targeted therapy. Although these treatments offer hope and broader prospects for patients, challenges persist. Through a systematic review of the literature from PubMed and Web of Science over the past decade, a summary and analysis of treatment trends, existing challenges and the latest research developments in advanced GBC were provided.

Indexed as

chemoradiotherapygallbladder cancerimmunotherapylocal therapy

Identifiers

PMID40510236
PMCPMC12159723

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.